Furthermore, preliminary results from the ENCORE-601 phase Ib/II trial revealed that entinostat, an experimental HDAC inhibitor, was well tolerated and, together with pembrolizumab, induced durable responses in melanoma patients whose disease progressed after PD-1 blockade monotherapy [150]. The gene discussed is HDAC9; the disease is melanoma.